论文部分内容阅读
目的 :对 78例脑胶质瘤术后接受单纯放疗或同步放化疗的患者进行回顾性生存分析。方法 :1 987年 1 1月～ 1 995年 5月间收治 78例脑胶质瘤患者 ,根据术后治疗方案不同分为两组。单纯放疗组 ,给予术后放疗 ,总剂量为 5 5Gy～ 60Gy;同步放化疗组 ,采用静脉给药或颈动脉插管给药。化疗与放疗同步进行。 结果 :单纯放疗组和同步放化疗组的中位生存期分别为 4 0个月和 3 6个月 ,两组无显著性差异 (P >0 .0 5 )。但是 ,从生存曲线上可以看出 ,当病理为Ⅰ、Ⅱ级时 ,单纯放疗组略好于同步放化疗组 ;病理为Ⅲ、Ⅳ级时 ,同步放化疗组略好于单纯放疗组。结论 :单纯放疗组的中位生存期与同步放化疗组之间无显著性差异。但通过分析各组的生存曲线 ,对病理为Ⅰ、Ⅱ级的脑胶质瘤患者 ,不提倡做术后化疗 ;病理为Ⅲ、Ⅳ级时 ,一般状况较好的患者可以进行术后放疗加化疗的综合治疗
Objective: To retrospectively analyze the survival of 78 patients with glioma who underwent radiotherapy alone or concurrent chemoradiotherapy. Methods: Between January 1987 and January 1995, 78 patients with glioma were enrolled and divided into two groups according to the postoperative treatment plan. Simple radiotherapy group, given postoperative radiotherapy, the total dose of 5Gy ~ 60Gy; concurrent radiotherapy and chemotherapy group, intravenous or carotid catheterization. Chemotherapy and radiotherapy simultaneously. Results: The median survival time of radiotherapy alone group and concurrent chemoradiotherapy group was 40 months and 36 months, respectively. There was no significant difference between the two groups (P> 0.05). However, from the survival curve, we can see that the radiotherapy group is slightly better than the concurrent radiotherapy and chemotherapy group when the pathology is grade Ⅰ and Ⅱ, while the radiotherapy group is slightly better than the radiotherapy group when the pathology is grade Ⅲ and Ⅳ. Conclusion: There is no significant difference between median survival time and concurrent chemoradiotherapy in radiotherapy alone group. However, by analyzing the survival curves of each group, patients with pathological grade Ⅰ and Ⅱ gliomas are not advocated for postoperative chemotherapy; when the pathology is grade Ⅲ and Ⅳ, patients with better general status can be treated with postoperative radiotherapy The comprehensive treatment of chemotherapy